Want to see BVNRY full AI Analyst Report?
BVNRY Stock Chart & Stats
$10.36
-$0.28(-3.01%)
At close: 4:00 PM EST
$10.36
-$0.28(-3.01%)
Day’s Range― - ―
52-Week Range$8.81 - $12.54
Previous CloseN/A
Volume6.49K
Average Volume (3M)793.00
Market Cap
$2.21B
Enterprise Value$13.39B
Total Cash (Recent Filing)$2.29B
Total Debt (Recent Filing)$139.42M
Price to Earnings (P/E)12.5
Beta1.04
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.87
Shares Outstanding237,712,550
10 Day Avg. Volume0
30 Day Avg. Volume793
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.15
Price to Sales (P/S)2.49
P/FCF Ratio6.11
Enterprise Value/Market Cap6.07
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit4.77
Enterprise Value/Ebitda5.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage (debt-to-equity ~0.01) provides durable financial flexibility to fund operations, absorb government payment timing swings, pursue selective M&A or return capital, and materially lowers solvency risk versus peers—supporting long-term operational resilience.
Sustained Profitability & Margin UpsideThe company has moved from multi-year losses to sustained profitability (TTM net margin near 20%) and management increased 2026 EBITDA margin guidance to ~28%. This demonstrates durable operating leverage, better cost control and improving unit economics tied to manufacturing scale.
Secured Public Preparedness Contracts & BARDA OrdersMeaningful, repeatable government contract backlog (DKK 2.0bn secured, additional DKK 300–500m expected, BARDA orders and >$1.2bn history) gives multi-quarter revenue visibility, supports steady manufacturing throughput and underpins embedded demand independent of commercial cycles.
Bears Say
Revenue Volatility & Lumpy Public PreparednessTop-line shows choppiness (TTM revenue decline ~4.6%) and public preparedness contract timing causes quarter-to-quarter volatility. This lumpy demand pattern complicates forecasting, can create margin swings from phasing, and reduces predictability of sustained organic growth rates.
U.S. Regulatory/Guideline Timing Risk For VimkunyaU.S. uptake of the chikungunya vaccine is materially tied to CDC publication and guidance; a 12–18 month delay is a structural regulatory dependency that can meaningfully slow the product revenue ramp in the largest market, lengthening payback timelines for launch investments.
Cash Conversion & Timing SensitivityWhile cash balances are healthy, free-cash-flow to net-income is uneven (~0.58) and Q1 showed negative operating cash flow due to a large milestone payment. This highlights working-capital and milestone timing risk that can constrain discretionary spending or buybacks if such events recur.
Bavarian Nordic News
BVNRY FAQ
What was Bavarian Nordic A/S’s price range in the past 12 months?
Bavarian Nordic A/S lowest stock price was $8.80 and its highest was $12.54 in the past 12 months.
What is Bavarian Nordic A/S’s market cap?
Bavarian Nordic A/S’s market cap is $2.21B.
When is Bavarian Nordic A/S’s upcoming earnings report date?
Bavarian Nordic A/S’s upcoming earnings report date is Aug 21, 2026 which is in 51 days.
How were Bavarian Nordic A/S’s earnings last quarter?
Bavarian Nordic A/S released its earnings results on May 13, 2026. The company reported $0.012 earnings per share for the quarter, beating the consensus estimate of N/A by $0.012.
Is Bavarian Nordic A/S overvalued?
According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued.
Does Bavarian Nordic A/S pay dividends?
Bavarian Nordic A/S pays a Notavailable dividend of $0.426 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here
What is Bavarian Nordic A/S’s EPS estimate?
Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bavarian Nordic A/S have?
Bavarian Nordic A/S has 237,712,550 shares outstanding.
What happened to Bavarian Nordic A/S’s price movement after its last earnings report?
Bavarian Nordic A/S reported an EPS of $0.012 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.315%.
Which hedge fund is a major shareholder of Bavarian Nordic A/S?
Currently, no hedge funds are holding shares in BVNRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bavarian Nordic Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.68%
12-Months-Change
Fundamentals
Return on Equity
9.25%
Trailing 12-Months
Asset Growth
10.81%
Trailing 12-Months
Company Description
Bavarian Nordic A/S
Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA). The company also boasts a robust pipeline of investigational therapies. Notably, MVA-BN (freeze-dried) has concluded Phase III trials for smallpox, and MVA-BN RSV is currently in Phase III clinical development for respiratory syncytial virus (RSV). Additionally, ABNCoV2, a candidate for SARS-CoV-2, successfully completed its Phase II clinical trial, and TAEK-VAC is advancing through Phase I/II studies for select advanced HER2 and brachyury-expressing cancers. Bavarian Nordic maintains strategic alliances, including a licensing and collaboration agreement with AdaptVac, alongside further licensing arrangements with the National Cancer Institute and the Public Health Service. Its commercial operations and presence span numerous countries, such as the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan, reflecting a broad international footprint. Established in 1992, Bavarian Nordic A/S is headquartered in Hellerup, Denmark.
BVNRY Company Deck
BVNRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear positives: solid Q1 revenue (DKK 1.058b), Travel Health growth (14%), successful global rollout of Vimkunya with DKK 41m in Q1, a meaningful BARDA order that completed a long-term freeze-dried contract and led management to raise full-year revenue guidance to DKK 5.5–5.7b and EBITDA margin to ~28%. Management highlighted strong manufacturing performance, secured Public Preparedness revenues (DKK 2.0b secured with DKK 300–500m expected more), and progress on key R&D readouts (Phase II cell-line interim data due later in 2026). The principal negatives are operational timing risks and one-off cash outflows: U.S. regulatory/publication delays (CDC MMWR) creating headwinds for U.S. uptake of Vimkunya, Encepur inventory/shelf-life timing effects that pressured reported Q1 product sales (though market share and market growth are healthy), negative Q1 operating cash flow impacted by milestone payments, and staged pipeline advancement. Overall, positives (raised guidance, contract wins, product rollouts and strong Travel Health metrics) appear to outweigh the manageable and largely timing-related lowlights.View all BVNRY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---